Diclofenac use and cardiovascular risks

Using nationwide health registry data from 1996–2016, Danish researchers analyzed the cardiovascular (CV) risks associated with diclofenac initiation. Outcomes from more than 1.3 million diclofenac initiators were compared with outcomes after initiation of other traditional NSAIDs or paracetamol, as well as with no initiation.

Using nationwide health registry data from 1996–2016, Danish researchers analyzed the cardiovascular (CV) risks associated with diclofenac initiation. Outcomes from more than 1.3 million diclofenac initiators were compared with outcomes after initiation of other traditional NSAIDs or paracetamol, as well as with no initiation. Outcomes included atrial fibrillation/flutter, ischemic stroke, heart failure, myocardial infarction, and cardiac death. The rate of adverse CV events within 30 days increased in diclofenac initiators by more than 50% compared with an estimated 1.3 million non-initiators, by 30% compared with 291,490 naproxen initiators, and by 20% compared with 764,781 paracetamol and more than 3.8 million ibuprofen initiators. According to the investigators at Aurhaus University Hospital, the findings link starting on diclofenac to CV health risks compared with non-initiation, paracetamol use, and use of other traditional NSAIDs.